D Alarcon Segovia
- Prophylaxis of the antiphospholipid syndrome: a consensus reportD Alarcon-Segovia
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico DF, Mexico
Lupus 12:499-503. 2003..In no instance should corticosteroids or immunosuppresants be given as prophylactic of an antiphospholipid syndrome...
- The future of treatment for systemic lupus erythematosusD Alarcon-Segovia
Department of Immunology and Rheumatology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico
Isr Med Assoc J 3:127-30. 2001..All these treatment strategies will gradually become decanted in order to achieve the optimal treatment of SLE, which may tum out to be its cure...
- Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosusA R Cabral
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Lupus 13:182-7. 2004..In contrast, anti-beta2GP1 from patients with APS(+)/aPL(-) are blocked by cardiolipin, suggesting that their epitope is the phospholipid-binding site...
- Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosusM Valencia-Flores
Departamento de Neurologia y Psiquiatra, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Delegacion Tlalpan, Mexico 14000, DF, Mexico
Lupus 13:4-10. 2004..Fibromyalgia is not common in Mexican patients with SLE and has a different pattern of symptoms in RP and NP patients. These data add evidence that ethnicity can play an important role in FM manifestations...